About Alloy Therapeutics
Alloy Therapeutics is a company based in Lexington (United States) founded in 2017. Alloy Therapeutics has raised $117 million across 3 funding rounds from investors including ARE, Mubadala and 8VC. Alloy Therapeutics has completed 1 acquisition, including deepCDR Biologics. Alloy Therapeutics offers products and services including Antibody Platforms, TCR Mimics, and Genetic Medicines. Alloy Therapeutics operates in a competitive market with competitors including Evotec, Crown Bioscience, Domainex, NIH and Viva Biotech, among others.
- Headquarter Lexington, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alloy Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$117 M (USD)
in 3 rounds
-
Latest Funding Round
Not available
-
Investors
ARE
& 8 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alloy Therapeutics
Alloy Therapeutics offers a comprehensive portfolio of products and services, including Antibody Platforms, TCR Mimics, and Genetic Medicines.
End-to-end services for monoclonal and bispecific discovery
Platform for targeting intracellular peptides in oncology
Services for improving potency and delivery of ASO candidates
People of Alloy Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Alloy Therapeutics
Alloy Therapeutics has successfully raised a total of $117M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alloy Therapeutics
Alloy Therapeutics has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include ARE, Mubadala and 8VC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in technology, life sciences, and related sectors.
|
Locked | Locked | Locked | |
|
Thiel Capital is involved in investment and financial activities.
|
Locked | Locked | Locked | |
|
Venture capital fund backed by the Christian family office
|
Locked | Locked | Locked |
Investor details for Alloy Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alloy Therapeutics
Alloy Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include deepCDR Biologics.
Investment portfolio details for Alloy Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Diagnostic and pharmaceutical products are manufactured by deepCDR Biologics.
|
Locked | Locked | 2019 | Locked |
Complete acquisition details for Alloy Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Alloy Therapeutics
Detailed financials for Alloy Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alloy Therapeutics Comparisons
Peer comparison for Alloy Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alloy Therapeutics
Alloy Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evotec, Crown Bioscience, Domainex, NIH and Viva Biotech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery and development services are provided to biopharma sector.
|
|
| Locked | Locked | Locked |
Cancer and CVMD drugs are developed using PDX models.
|
|
| Locked | Locked | Locked |
Drug discovery CRO company for epigenetic research and inflammatory diseases
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to the biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery and development research services are provided.
|
Detailed competitors of Alloy Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alloy Therapeutics
Complete news archive for Alloy Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alloy Therapeutics
Alloy Therapeutics was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Alloy Therapeutics is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Alloy Therapeutics is a funded company, having raised a total of $117M across 3 funding rounds to date.
Alloy Therapeutics was founded in 2017 and is headquartered in Lexington, United States. Operations focus on the biotechnology sector, where drug discovery services are delivered to support pharmaceutical innovation. Expertise is applied in early-stage research and development processes, including target identification and validation. The companys platform facilitates collaborative efforts with partners across the industry, emphasizing efficient workflows in therapeutic advancement.
Alloy Therapeutics's top competitors include Evotec, Crown Bioscience and NIH.
Alloy Therapeutics offers Antibody Platforms, TCR Mimics, and Genetic Medicines.
Alloy Therapeutics has made 1 acquisition, including deepCDR Biologics.
Alloy Therapeutics has 9 investors. Key investors include ARE, Mubadala, 8VC, Thiel Capital, and Presight Capital.